Literature DB >> 11423911

Sensitivity of Ewing's sarcoma to TRAIL-induced apoptosis.

H U Kontny1, K Hämmerle, R Klein, P Shayan, C L Mackall, C M Niemeyer.   

Abstract

Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is able to kill transformed cells. We have studied the expression and functionality of the TRAIL apoptotic pathway in Ewing's sarcoma. We demonstrate that tumors from patients with Ewing's sarcoma express receptors TRAIL-R1 and -R2. Using a panel of nine Ewing's sarcoma cell lines TRAIL could induce apoptosis in seven cell lines. Preincubation with interferon-gamma rendered the two resistant cell lines sensitive. TRAIL was the most potent inducer of apoptosis when compared to Fas ligand or TNF. TRAIL-mediated apoptosis could be inhibited by various caspase-inhibitors. No difference in the surface expression of TRAIL-receptors was observed between sensitive and resistant cell lines. Also, all cell lines had similar levels of expression of Flice-like inhibitory protein (FLIP) on immunoblot. However, the two resistant cell lines had only very low level expression of caspase 8 on RNA and protein level. In summary, we show that Ewing's sarcoma expresses receptors for TRAIL, and that cells are exquisitely sensitive to TRAIL-mediated apoptosis. These results may warrant clinical trials with TRAIL in Ewing's sarcoma once the safety of TRAIL for humans has been established.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11423911     DOI: 10.1038/sj.cdd.4400836

Source DB:  PubMed          Journal:  Cell Death Differ        ISSN: 1350-9047            Impact factor:   15.828


  18 in total

1.  ML327 induces apoptosis and sensitizes Ewing sarcoma cells to TNF-related apoptosis-inducing ligand.

Authors:  Eric J Rellinger; Chandrasekhar Padmanabhan; Jingbo Qiao; Andrew Appert; Alex G Waterson; Craig W Lindsley; R Daniel Beauchamp; Dai H Chung
Journal:  Biochem Biophys Res Commun       Date:  2017-07-14       Impact factor: 3.575

2.  USP6 Confers Sensitivity to IFN-Mediated Apoptosis through Modulation of TRAIL Signaling in Ewing Sarcoma.

Authors:  Ian C Henrich; Robert Young; Laura Quick; Andre M Oliveira; Margaret M Chou
Journal:  Mol Cancer Res       Date:  2018-08-21       Impact factor: 5.852

3.  TRAIL receptor signaling and therapeutic option in bone tumors: the trap of the bone microenvironment.

Authors:  Gaëlle Picarda; Valérie Trichet; Stéphane Téletchéa; Dominique Heymann; Françoise Rédini
Journal:  Am J Cancer Res       Date:  2011-10-09       Impact factor: 6.166

Review 4.  Emerging chemotherapeutic strategies and the role of treatment stratification in Ewing sarcoma.

Authors:  Beatrice M Seddon; Jeremy S Whelan
Journal:  Paediatr Drugs       Date:  2008       Impact factor: 3.022

5.  Phase I trial and pharmacokinetic study of lexatumumab in pediatric patients with solid tumors.

Authors:  Melinda S Merchant; James I Geller; Kristin Baird; Alexander J Chou; Susana Galli; Ava Charles; Martha Amaoko; Eunice H Rhee; Anita Price; Leonard H Wexler; Paul A Meyers; Brigitte C Widemann; Maria Tsokos; Crystal L Mackall
Journal:  J Clin Oncol       Date:  2012-10-15       Impact factor: 44.544

6.  Targeted therapies for bone sarcomas.

Authors:  Dominique Heymann; Françoise Rédini
Journal:  Bonekey Rep       Date:  2013-07-17

7.  Interferon-gamma sensitizes resistant Ewing's sarcoma cells to tumor necrosis factor apoptosis-inducing ligand-induced apoptosis by up-regulation of caspase-8 without altering chemosensitivity.

Authors:  Andrej Lissat; Thomas Vraetz; Maria Tsokos; Ruth Klein; Matthias Braun; Nino Koutelia; Paul Fisch; Maria E Romero; Lauren Long; Peter Noellke; Crystal L Mackall; Charlotte M Niemeyer; Udo Kontny
Journal:  Am J Pathol       Date:  2007-06       Impact factor: 4.307

8.  IFN regulatory factor 8 sensitizes soft tissue sarcoma cells to death receptor-initiated apoptosis via repression of FLICE-like protein expression.

Authors:  Dafeng Yang; Suizhao Wang; Craig Brooks; Zheng Dong; Patricia V Schoenlein; Vijay Kumar; Xinshou Ouyang; Huabao Xiong; Guy Lahat; Andrea Hayes-Jordan; Alexander Lazar; Raphael Pollock; Dina Lev; Kebin Liu
Journal:  Cancer Res       Date:  2009-01-20       Impact factor: 12.701

9.  Fas/Fas ligand regulation mediates cell death in human Ewing's sarcoma cells treated with melatonin.

Authors:  G García-Santos; V Martin; J Rodríguez-Blanco; F Herrera; S Casado-Zapico; A M Sánchez-Sánchez; I Antolín; C Rodríguez
Journal:  Br J Cancer       Date:  2012-03-01       Impact factor: 7.640

10.  Activating Death Receptor DR5 as a Therapeutic Strategy for Rhabdomyosarcoma.

Authors:  Zhigang Kang; Shi-Yong Sun; Liang Cao
Journal:  ISRN Oncol       Date:  2012-04-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.